LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the tuberculosis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat tuberculosis.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING
Tuberculosis: Market overview
Tuberculosis is a disease caused by a bacterium called Mycobacterium tuberculosis. This bacterium is present in the air and spreads from one person to another. It usually affects the lungs and can also target other body parts, including the spine, brain, and kidney.
According to a senior market research analyst at Technavio for research on infectious and rare diseases, “Research study shows that 10.4 million people worldwide became sick with tuberculosis in 2016. Furthermore, 1.7 million TB-related deaths were reported worldwide. In 2012, there were 122 cases per 100,000 population, in which most of the cases were from Africa, Western Pacific, Eastern Mediterranean region, Europe, and the Americas.”
Tuberculosis: Segmentation analysis
This pipeline analysis report segments the tuberculosis market based on therapies employed (monotherapy and combination therapy), RoA (oral, intradermal, intramuscular, and subcutaneous), therapeutic modality (small molecule, vaccine, and biological), targets (cell wall, DprE1 protein, adenosine triphosphatase, fatty acid synthetase complex, leucyl-tRNA synthetase, mycobacterial DNA, phosphotransferase, protein 30S ribosomal subunit, protein kinase, and protein synthesis), MoA (immune stimulator, cell wall inhibitor, DprE1 protein inhibitor, adenosine triphosphatase inhibitor, fatty acid synthetase complex inhibitor, leucyl-tRNA synthetase inhibitor, mycobacterial DNA inhibitor, phosphotransferase inhibitor, protein 30S ribosomal subunit inhibitor, protein kinase inhibitor, and protein synthesis inhibitor), geographical segmentation (the US, the Philippines, South Africa, Russia, Kenya, and India), and recruitment status (completed, recruiting, not yet recruiting, active,not recruiting, and terminated). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.